NASDAQ · ASBPW

Aspire Biopharma Holdings, Inc.

$0.02 +$0.00 (+11.63%) 1D Market open

Key Metrics

$758
Market cap
P/E · TTM
$34.56K
Revenue · TTM
−$11.76M
Net income
EPS · TTM $-372.52
Dividend yield
Free cash flow
Beta · 1Y 1.75
EBITDA · TTM
Gross margin 16.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    A material event was filed (Form 8-K).

    8-K - Aspire Biopharma Holdings, Inc. (0001847345) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 23
    The stock moved +53.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 23
  • Jun 11
    The stock moved +58.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 11
  • Apr 16
    From its Jan 30 high, the share price fell 59%.

    Peak close $0.03 on Jan 30; trough close $0.01 on Apr 16. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -59%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.01 – $0.08
Avg volume · 20D36.2K
Net cash
Book value / share$122.52
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Aspire Biopharma Holdings, Inc.
IPO dateFeb 20, 2025
Employees

Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.02
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 16.3%
Operating -60,765.3%
Net -34,039.7%
FCF
ROE / ROIC 201.0% · —

Financial Health

Current ratio2.26
Quick ratio2.14
Debt / equity
Debt / EBITDA
Net cash
Working capital$3.96M

Cash Flow · TTM

Operating CF −$6.21M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-15.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings